HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology
company with fully integrated commercial and drug development operations
with a primary focus in Hematology and Oncology, will be hosting its
fourth quarter 2014 financial results and analyst day in New York City
on Friday, March 13, 2015 from 10:00 a.m. to 12:00 p.m. ET.
Spectrum's management and external experts will provide an update on the
Company's business and discuss the Company's development portfolio.
Spectrum speakers scheduled to present include:
Rajesh Shrotriya, M.D., Chairman of the Board and Chief Executive Officer
Turgeon, President and Chief Operating Officer
Executive Vice President, Chief Financial Officer and Principal
Lee Allen, M.D., Chief Medical Officer
Riga, Senior Vice President and Chief Commercial Officer
Four external key opinion leaders scheduled to present include:
Francisco Esteva, M.D., PhD
Professor of Medicine, Director, Breast
Medical Oncology Associate, Director of Clinical Investigation, Laura
and Isaac Perlmutter Cancer Center New York University Langone Medical
Parameswaran Hari, M.D., MRCP, MS
Armand J. Quick/William F. Stapp
Professor of Hematology at the Medical College of Wisconsin, Director of
the Adult Blood and Marrow Transplant Program at Froedtert Hospital and
the Section Head of Hematologic Malignancies and Transplantation, in the
Division of Hematology and Oncology in the Department of Medicine.
Jeffrey L. Vacirca, M.D., FACP
CEO, Managing Partner & Chief of
Clinical Research at North Shore Hematology/Oncology Associates Medical
Director for ION/ASBSG Vice-President, Community Oncology Alliance CEO &
President National Translational Research Group.
Prof Dr. JA Witjes, M.D., PhD
Staff Member in the Department of
Urology, The Radboud University Nijmegen Medical Center, Member of the
Faculty of the European School of Urology and Chair of the Dutch
Guidelines Committee on Bladder Cancer and the EAU Guidelines Committee
on Metastatic and Muscle-Invasive Bladder Cancer.
Friday, March 13, 2015 @ 10:00 a.m.
Eastern/7:00 a.m. Pacific
(877) 837-3910, Conference ID# 82077760
(973) 796-5077, Conference ID# 82077760
For interested individuals unable to join the call, a replay will be
available from March 13, 2015 @ 2:00 p.m. ET/11:00 a.m. PT through March
26, 2015 until 11:59 p.m. ET/8:59 p.m. PT.
Domestic Replay Dial-In #:
(855) 859-2056, Conference ID# 82077760
International Replay Dial-In #:
(404) 537-3406, Conference ID# 82077760
This conference call will also be webcast. Listeners may access the
webcast, which will be available on the investor relations page
of Spectrum Pharmaceuticals' website: www.sppirx.com on March
13, 2015 at 10:00 a.m. Eastern/7:00 a.m. Pacific.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company focused on
acquiring, developing, and commercializing drug products, with a primary
focus in oncology and hematology. Spectrum and its affiliates market
five oncology drugs─ FUSILEV® (levoleucovorin) for Injection
in the U.S.; FOLOTYN® (pralatrexate injection), also marketed
in the U.S.; ZEVALIN® (ibritumomab tiuxetan) Injection for
intravenous use, for which the Company has worldwide marketing rights;
MARQIBO® (vinCRIStine sulfate LIPOSOME injection) for
intravenous infusion, for which the Company has worldwide marketing
rights and BELEODAQ® (belinostat) for Injection in the
U.S.. Spectrum's strong track record in in-licensing and acquiring
differentiated drugs, and expertise in clinical development have
generated a robust, diversified, and growing pipeline of product
candidates in advanced-stage Phase 2 and Phase 3 studies. More
information on Spectrum is available at www.sppirx.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially. These
statements are based on management's current beliefs and expectations.
These statements include, but are not limited to, statements that
relate to our business and its future, including certain company
milestones, Spectrum's ability to identify, acquire, develop and
commercialize a broad and diverse pipeline of late-stage clinical and
commercial products, leveraging the expertise of partners and employees
around the world to assist us in the execution of our strategy, and any
statements that relate to the intent, belief, plans or expectations of
Spectrum or its management, or that are not a statement of historical
fact. Risks that could cause actual results to differ include the
possibility that our existing and new drug candidates may not prove safe
or effective, the possibility that our existing and new applications to
the FDA and other regulatory agencies may not receive approval in a
timely manner or at all, the possibility that our existing and new drug
candidates, if approved, may not be more effective, safer or more cost
efficient than competing drugs, the possibility that our efforts to
acquire or in-license and develop additional drug candidates may fail,
our lack of sustained revenue history, our limited marketing experience,
our dependence on third parties for clinical trials, manufacturing,
distribution and quality control and other risks that are described in
further detail in the Company's reports filed with the Securities and
Exchange Commission. We do not plan to update any such
forward-looking statements and expressly disclaim any duty to update the
information contained in this press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC.®, FUSILEV®,
FOLOTYN®, ZEVALIN®, MARQIBO®,
and BELEODAQ® are registered trademarks of Spectrum
Pharmaceuticals, Inc and its affiliates. REDEFINING CANCER CARE™
and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum
Pharmaceuticals, Inc. Any other trademarks are the property of
their respective owners.
© 2015 Spectrum Pharmaceuticals, Inc. All Rights Reserved
Spectrum Pharmaceuticals, Inc.
President, Strategic Planning & Investor Relations
Source: Spectrum Pharmaceuticals, Inc.
News Provided by Acquire Media